News

Imago BioSciences Granted Fast Track Designation for IMG-7289 in Essential Thrombocythemia

Imago BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of Essential Thrombocythemia.

January New Donor Challenge

An anonymous donor has come forward and offered to MATCH all gifts made to the MPN Research Foundation by NEW donors all through January!

2019 ASH Meeting Report

John Crispino PhD, MBA and Rick Winneker, PhD reports on MPN updates from the 2019 ASH Meeting.

New Clinical Trial Available Myelofibrosis Patients

Actuate Therapeutics Inc. is recruiting patients for Actuate 1901: 9-ING-41, a phase 2 study that will study its efficacy in patients with advanced myelofibrosis.

Research into rare blood cancers called myeloproliferative neoplasms goes global

MPN advocacy organizations are working together across borders to ensure that people living with polycythemia vera, essential thrombocythemia and myelofibrosis will have their treatment needs met by investing in research.

Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis

Sierra Oncology announced today that it has launched the Phase 3 MOMENTUM clinical trial for Myelofibrosis patients

Call for MPN drug to be approved in Australia

"There's actually an even longer-acting version of the drug, an ultra-long-acting version, which has been approved in Europe but not Australia, and we'd like to see that approved here."

Pegylated Interferon Benefits High-Risk MPNs Previously Treated With Hydroxyurea

According to a study published in Blood, Pegylated interferon proved to be effective for patients with high-risk ET and PV.

New Clinical Trials Available for MPN Patients

Vactosertib and PRT543 are now available.

Patient Power's MPN Patient Survey

As researchers around the world seek to accelerate progress in medicine it's important for patients to share their stories to promote greater understanding. Patient Power has partnered with Dr. Naveen Pemmaraju to find out more about how patients use online resources to guide their car

New Trial Recruiting Primary, Post-PV, and Post-ET Myelofibrosis Patients

CTI Biopharma is recruiting patients for the PACIFCA trial, a randomized phase 3 study evaluating PACRITINIB in patients with MF.

The Fall 2019 Newsletter is Here

Your copy of the Fall 2019 Newsletter from the MPN Research Foundation is now available.

Pegylated Interferon Leads to High Response Rates in ET & PV After Hydroxyurea

ASH Clinical News reports on the results of an open-label, phase II clinical trial published in Blood.

Today is Rare Cancer Day!

The big day is here - Rare Cancer Day! Launched by the National Organization for Rare Disorders (NORD) and the NORD Rare Cancer Coalition, the goal of #RareCancerDay is to raise critical awareness of rare cancers and the need for greater research funding and patient support.